|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||8.65 - 8.65|
|52-week range||6.00 - 12.30|
|Beta (5Y monthly)||1.21|
|PE ratio (TTM)||64.07|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Clinigen Group plc ( LON:CLIN ), might not be a large cap stock, but it saw a double-digit share price rise of over 10...
BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...